Crossovers bet big before the bell
- 01Theme 1: Crossover Investors Are Making Unprecedented, Hyper-Concentrated Pre-IPO Bets
- 02Theme 2: Private Capital Advisory Is Consolidating as Secondary Markets Go Mainstream
- 03Theme 3: Healthtech Is Sustaining Strong VC Momentum
- 04Theme 4: North American Buyers Are Bargain-Hunting in Europe
- 05Theme 5: "Greenhushing"
1. Key Themes
Theme 1: Crossover Investors Are Making Unprecedented, Hyper-Concentrated Pre-IPO Bets
Crossover firms dramatically shifted strategy in Q1 2026, abandoning breadth for massive concentration in a handful of elite pre-IPO companies. US crossover deal value hit a record $220.9 billion across only 178 deals — a stark contrast to the 425 deals of Q4 2021's prior peak of $50.3 billion.
"Crossovers were already invested in the mega IPO companies, so much of it is follow-on, rather than getting in. These deals are unprecedented in size, and with that comes the need of large crossover investors to fill out the round." — Kyle Stanford, PitchBook Director of US VC Research
"It's almost like the 'Mag 7' equivalent in the private markets. It's hyper-focused in a very small [number of startups]... It's a very limited group of companies that they're looking to deploy into." — Samir Kaji, Allocate CEO
Theme 2: Private Capital Advisory Is Consolidating as Secondary Markets Go Mainstream
Lazard's $575M acquisition of Campbell Lutyens signals that scale is now a prerequisite in private capital advisory, particularly for secondary transactions. Investment banks are racing to build full-service platforms covering fundraising, secondaries, continuation funds, M&A, and restructuring under one roof.
"Lazard's move is part of a wave of consolidation in the private capital advisory market. Houlihan Lokey, Piper Sandler, Mizuho and Harris Williams are among the investment banks that have acquired secondary advisory and placement agent businesses in recent years."
"Increasingly, fund managers are exploring 'triple-track' processes, weighing an IPO, M&A and continuation funds simultaneously. Having all of this expertise in-house, at scale, is hugely useful."
Theme 3: Healthtech Is Sustaining Strong VC Momentum
Despite broader market uncertainty, healthtech VC activity maintained momentum in Q1 2026, with deal volume up 35.5% year-over-year, driven by wearables, behavioral health, and AI platforms.
"Healthtech VC activity maintained speed in Q1, with deal volume up 35.5% year-over-year, driven by standout raises in wearables, behavioral health and AI platforms."
Corroborating deal flow includes Iterative Health raising a $77M Series C (clinical research AI) and Photon raising a $16M Series A (prescription platform for health systems).
Theme 4: North American Buyers Are Bargain-Hunting in Europe
Transatlantic M&A surged to $117.5 billion in Q1 2026 alone, with the US-Europe valuation gap at its widest since 2022 — creating a structural acquisition opportunity for North American capital.
"North American buyers are bargain hunting in Europe — $117.5 billion in transatlantic M&A deals landed in Q1 alone, with the US-Europe valuation gap at its widest since 2022."
This is further reinforced by the Chart of the Day, which highlights Italy as a bright spot — VC deal count up 80% YoY (225 rounds in Q1 2026 vs. 125 in Q1 2025), bucking the declining trend across most European VC hubs.
Theme 5: "Greenhushing" — ESG Investing Is Alive but Going Underground
Fund managers are not retreating from sustainable investing, but they are becoming strategically silent about it to avoid political and regulatory scrutiny — a trend dubbed "greenhushing."
"Most fund managers haven't decreased their green investing efforts, but are selective about how and why they use sustainability-focused language."
2. Contrarian Perspectives
Contrarian 1: The Crossover Surge May Be a Bubble Setup, Not a Signal of Strength
While record crossover deal values look bullish on the surface, the concentration into a tiny number of mega-deals at unprecedented valuations draws uncomfortable historical parallels to 2021 — a period that preceded significant private market corrections.
"It's a little bit like 2021… they bought heavily into the pre-IPO rounds… Time will tell: Sometimes it ends well, and sometimes it ends badly." — Steve Kaplan, Professor, University of Chicago Booth School of Business
The data amplifies the concern: Q1 2026 deal value of $220.9 billion across just 178 deals is more than four times the prior peak of $50.3 billion (Q4 2021), yet deal count is at similar low levels. The risk of a small number of IPOs disappointing could trigger outsized portfolio damage for crossover funds.
Contrarian 2: Mega IPOs May Cannibalize — Not Validate — the Broader 2026 IPO Class
The conventional narrative is that a strong mega-IPO pipeline (e.g., OpenAI, Anthropic) signals a healthy IPO market. PitchBook's own related research challenges this: "Mega IPOs Could Threaten 2026 IPO Class." Investor attention and capital are finite — a handful of trillion-dollar listings may crowd out mid-market IPOs seeking allocations and attention from institutional buyers.
Contrarian 3: Greenhushing Suggests ESG Is More Durable Than the Backlash Implies
The mainstream narrative has been that ESG investing is in retreat due to political pressure. The contrarian read from this issue is that ESG activity has not materially declined — managers are simply rebranding how they communicate it.
"Most fund managers haven't decreased their green investing efforts, but are selective about how and why they use sustainability-focused language."
This implies that ESG-focused companies and fund managers who interpret the current environment as a permanent shift may be miscalibrating their strategy.
3. Companies Identified
| Company | Description | Why Mentioned | Key Quote |
|---|---|---|---|
| OpenAI | AI research and deployment company | Raised $110B round with crossover investors Altimeter, Coatue, D.E. Shaw | Cited as central example of "unprecedented" mega pre-IPO deals |
| Anthropic | AI safety and research company | Raised $30.6B Series G; Coatue, GIC, D.E. Shaw led; hedge funds Appaloosa, NX1, Whale Rock, XN also invested | Second anchor of the crossover concentration trend |
| Lazard | 177-year-old investment bank | Acquired Campbell Lutyens for ~$575M to build out private capital advisory | "The combination gives Lazard the scale to better compete against rivals such as Evercore and Jefferies" |
| Campbell Lutyens | London-based fund placement and secondaries advisory firm | Acquired by Lazard; advised on some of the largest infrastructure and private credit continuation funds | Highlighted as the strategic asset Lazard needed for "triple-track" process expertise |
| Revolut | Global fintech | Noted as scaling toward a $200B IPO; flagged for growth dependency on traditional lending expansion | "Its long-term growth depends on whether it can successfully expand into traditional lending, where it currently lags behind established banks" |
| Netomi | AI customer service platform | Raised $110M led by Accenture Ventures | Largest VC deal noted in the issue |
| Iterative Health | Healthtech/clinical research AI | Raised $77M Series C (Intrepid Growth Partners, GV) | Part of healthtech deal momentum theme |
| JuliaHub | Scientific machine learning | Raised $65M Series B led by Dorilton Capital | Notable deep-tech raise |
| CMBlu Energy | German energy storage | Raised €50M Series C (Samsung Ventures); €1B valuation | European deep-tech/energy storage funding |
| Legora | Stockholm-based legal AI | Raised $50M Series D extension (Atlassian, Airtree, NVentures); $5.6B valuation, $600M total round | Signals rapid legal AI valuation escalation |
| Versana | Enterprise data for private credit market | Raised $43M led by BNP Paribas | Infrastructure play on private credit market growth |
| Featherless | AI inference | Raised $20M Series A (AMD Ventures, Airbus Ventures) | Strategic corporate investor backing in AI inference |
| Groove Quantum | Dutch quantum computing | Raised €16M seed (Innovation Industries, 55 North) | European deep-tech seed; quantum category |
| Moleculent | Swedish cell-mapping life sciences | Raised $20M Series A (Rubicon Healthcare Partners) | European life sciences innovation |
| Squads | Financial infrastructure (Solana ecosystem) | Raised $18M (Solana Ventures) | Crypto/DeFi infrastructure signal |
| LNG Canada | Liquefied natural gas project | Shell's $10-15B stake being bid on by Apollo, Blackstone, KKR | Mega PE energy infrastructure deal |
| Helix Digital Infrastructure | AI infrastructure developer | Launched by KKR with $10B | KKR's aggressive bet on AI physical infrastructure |
| Tenneco | Auto parts supplier | Apollo considering $14B IPO | PE exit pipeline signal |
| Flora Food Group | Plant-based food (Netherlands) | KKR exploring $10B exit | Notable consumer PE exit in progress |
| Avalyn | Biopharma (lung diseases) | Raised $300M in US IPO; backed by SR One and Novo Nordisk | Successful biopharma IPO execution |
| CVC Capital Partners | Global PE/alternative asset manager | Private wealth segment grew 40%+ QoQ to €5.2B | Signals strong retail/HNW appetite for private markets access |
| Investindustrial | European mid-market PE | Closed €1.5B Lower Mid-Market IV fund at hard cap in under 4 months | Fast fundraise signals LP demand for European mid-market exposure |
| Blue Owl | Alternative asset manager (BDC) | BDC redemption requests concentrated among minority of investors | BDC liquidity dynamics worth monitoring |
4. People Identified
| Person | Description | Why Mentioned | Key Quote |
|---|---|---|---|
| Kyle Stanford | Director of US Venture Capital Research, PitchBook | Primary analyst commenting on crossover investor trend | "These deals are unprecedented in size, and with that comes the need of large crossover investors to fill out the round." |
| Samir Kaji | CEO, Allocate | Provided market framing on the hyper-concentration of crossover capital | "It's almost like the 'Mag 7' equivalent in the private markets. It's hyper-focused in a very small [number of startups]." |
| Steve Kaplan | Professor, University of Chicago Booth School of Business | Academic perspective grounding the current crossover surge in historical context | "It's a little bit like 2021… they bought heavily into the pre-IPO rounds… Time will tell: Sometimes it ends well, and sometimes it ends badly." |
| Peter Orszag | CEO and Chairman, Lazard | Articulated Lazard's long-term strategy behind the Campbell Lutyens acquisition | The deal "marks another defining strategic step on the path towards Lazard 2030," a plan to make Lazard less dependent on traditional M&A and restructuring |
| Peter Ogilvie | Newly appointed COO and Head of Strategy, Ares Management | C-suite appointment at a leading alternative asset manager | Noted for appointment; no direct quote provided |
5. Operating Insights
Insight 1: Pre-IPO Companies Should Begin Public-Company Operational Readiness Early — Not at Filing
IPO success is increasingly a function of how early companies build public-company-grade infrastructure. The DFIN/NetSuite IPO Readiness Checklist signals that governance, financial controls, and reporting systems need to be in place well before an offering is on the horizon — not as a last-minute scramble.
"IPO success increasingly depends on how early companies begin preparing for life as a public entity, from governance and financial reporting to controls, technology, and advisory readiness."
Insight 2: Fund Managers Should Adopt "Triple-Track" Strategic Optionality
As private market exit complexity increases, sophisticated fund managers are simultaneously evaluating IPO, M&A, and continuation fund paths — and the advisory infrastructure is now consolidating to support this.
"Increasingly, fund managers are exploring 'triple-track' processes, weighing an IPO, M&A and continuation funds simultaneously. Having all of this expertise in-house, at scale, is hugely useful."
Operators preparing for exits should structure their businesses and governance to be compatible with all three paths from the start, rather than optimizing for one.
Insight 3: ESG Language Strategy Matters as Much as ESG Action
For operators and fund managers with genuine sustainability practices, the current political environment demands careful communication strategy — not retreat. Managers who are continuing ESG practices but failing to frame them strategically may be leaving LP engagement and differentiation on the table.
"Most fund managers haven't decreased their green investing efforts, but are selective about how and why they use sustainability-focused language."
6. Overlooked Insights
Overlooked Insight 1: Italy Is the Breakout European VC Market — Up 80% YoY
While the newsletter briefly notes Italy in the Chart of the Day section, the magnitude is striking and underreported: Italy closed 225 VC rounds in Q1 2026, up 80% from 125 in Q1 2025, while most of Europe's key VC hubs saw declining deal counts. This may represent an early-stage opportunity for investors willing to look beyond the traditional London/Berlin/Stockholm corridors, particularly given the transatlantic valuation gap creating US buyer interest in European assets simultaneously.
Overlooked Insight 2: Cannabis-Based Medicine Unlocked as a New IPO and Funding Category
Briefly mentioned in the Side Letters, the FDA's reclassification of a cannabis ingredient has meaningfully changed the funding and IPO landscape for cannabis-derived pharmaceutical companies.
"Companies developing cannabis-based medicines now have real IPO and funding hopes. After the FDA's reclassification of the ingredient, these companies could now unlock more opportunities in private and public markets."
This is a regulatory-driven category unlock — the kind of inflection point that historically precedes a wave of formation activity and early-stage investment — and it received minimal emphasis relative to its potential significance.